Is Abbott Laboratories a Good Dividend Stock to Buy Now?
It's that time of year when Wall Street analysts start adjusting their predictions, and one dividend-paying stock, in particular, is getting a lot of positive attention.
Abbott Laboratories (NYSE: ABT) reported fourth-quarter earnings on Thursday, Jan. 26. Since then, Sanford C. Bernstein, Raymond James, Stifel Nicolaus, and Barclays have all raised their price targets on the healthcare conglomerate. The highest estimate, from Bernstein, implies a 19% gain from its latest closing price.
Is Abbott Laboratories a great dividend stock to buy, as Wall Street price targets would suggest? Let's weigh its weaknesses against its strengths to find out.
Source Fool.com